{"id":25025,"date":"2022-10-19T23:26:00","date_gmt":"2022-10-19T15:26:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25025"},"modified":"2025-02-02T23:30:12","modified_gmt":"2025-02-02T15:30:12","slug":"johnson-johnson-reports-q3-sales-growth-maintains-full-year-guidance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25025","title":{"rendered":"Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance"},"content":{"rendered":"\n

US giant Johnson & Johnson (J&J, NYSE: JNJ<\/a>) released its Q3 2022 financial report, showing global sales growth of 1.9% year-on-year (YOY) in reported terms to USD 23.8 billion. However, operational sales, excluding acquisitions, divestitures, and currency impacts, grew by 8.2%. This performance prompted the company to maintain its 2022 full-year guidance midpoints.<\/p>\n\n\n\n

Segment Performance<\/strong>
Pharmaceutical unit Janssen’s sales reached USD 13.2 billion, up 9.2% YOY (adjusted operational) globally, driven by strong performances in cancer, autoimmune diseases, and COVID-19 treatments. The consumer health segment expanded 4.8% to USD 3.8 billion, thanks to robust sales of upper respiratory and analgesic products. Medical device sales rose 8.1% YOY to USD 6.8 billion, with significant contributions from electrophysiology, contact lenses, and trauma products.<\/p>\n\n\n\n

Top Performing Pharmaceuticals<\/strong>
Pharmaceutical sales during the third quarter were led by autoimmune disease drug Stelara (ustekinumab) at USD 2.4 billion, multiple myeloma (MM) medicine Darzalex (daratumumab) at USD 2.1 billion, schizophrenia treatment Invega (paliperidone) at USD 1.0 billion, and B-cell malignancies therapy Imbruvica (ibrutinib) at USD 911 million.<\/p>\n\n\n\n

Carvykti: A USD 5 Billion+ Brand<\/strong>
During the earnings conference call, executives were questioned on the potential of Legend Biotech’s BCMA-targeted chimeric antigen receptor (CAR) T cell therapy Carvykti (ciltacabtagene autoleucel), which is under co-development with Janssen. Q3 marked the therapy’s second quarter on the market since its first approval in February 2022 for treating relapsed or refractory multiple myeloma (MM) in patients previously treated with four or more lines of therapy. Although J&J declined to release specific sales data for the drug, Jennifer Taubert, J&J’s worldwide chairman for pharmaceuticals, expressed strong confidence in the product’s prospects.<\/p>\n\n\n\n

Future Outlook for Carvykti<\/strong>
Carvykti’s initial launch in Q2 was impacted by a global shortage of lentivirus, which slowed manufacturing capabilities. However, Taubert noted that measures have been taken to ensure this will \u201cnot be a rate-limiting factor in the future\u201d and to scale up production beyond the initial clinical trial sites. Legend\/Janssen are looking forward to the Phase III CARTITUDE-4 study results \u201cbefore the end of the year,\u201d which, if successful, would allow the therapy to be used in patients previously treated with 1-3 lines of therapy. The CAR-T also has the potential to be used as a first-line therapy for MM if the CARTITUDE-5 Phase III study is successful. Given the potential for expanded use based on these studies, Taubert reconfirmed Carvykti as \u201ca big asset with a lot of growth potential and one of our potentially USD 5 billion-plus brands.\u201d-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,150,149,858],"class_list":["post-25025","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-jj","tag-johnson-johnson","tag-nyse-jnj"],"yoast_head":"\nJohnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing global sales growth of 1.9% year-on-year (YOY) in reported terms to USD 23.8 billion. However, operational sales, excluding acquisitions, divestitures, and currency impacts, grew by 8.2%. This performance prompted the company to maintain its 2022 full-year guidance midpoints.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25025\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25025\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-19T15:26:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-02T15:30:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25025#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25025\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance\",\"datePublished\":\"2022-10-19T15:26:00+00:00\",\"dateModified\":\"2025-02-02T15:30:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25025\"},\"wordCount\":418,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"J&J\",\"Johnson & Johnson\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25025#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25025\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25025\",\"name\":\"Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-10-19T15:26:00+00:00\",\"dateModified\":\"2025-02-02T15:30:12+00:00\",\"description\":\"US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing global sales growth of 1.9% year-on-year (YOY) in reported terms to USD 23.8 billion. However, operational sales, excluding acquisitions, divestitures, and currency impacts, grew by 8.2%. This performance prompted the company to maintain its 2022 full-year guidance midpoints.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25025#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25025\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25025#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance - Insight, China's Pharmaceutical Industry","description":"US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing global sales growth of 1.9% year-on-year (YOY) in reported terms to USD 23.8 billion. However, operational sales, excluding acquisitions, divestitures, and currency impacts, grew by 8.2%. This performance prompted the company to maintain its 2022 full-year guidance midpoints.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25025","og_locale":"en_US","og_type":"article","og_title":"Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25025","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-10-19T15:26:00+00:00","article_modified_time":"2025-02-02T15:30:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25025#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25025"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance","datePublished":"2022-10-19T15:26:00+00:00","dateModified":"2025-02-02T15:30:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25025"},"wordCount":418,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","J&J","Johnson & Johnson","NYSE: JNJ"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25025#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25025","url":"https:\/\/flcube.com\/?p=25025","name":"Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-10-19T15:26:00+00:00","dateModified":"2025-02-02T15:30:12+00:00","description":"US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing global sales growth of 1.9% year-on-year (YOY) in reported terms to USD 23.8 billion. However, operational sales, excluding acquisitions, divestitures, and currency impacts, grew by 8.2%. This performance prompted the company to maintain its 2022 full-year guidance midpoints.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25025#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25025"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25025#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25025"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25025\/revisions"}],"predecessor-version":[{"id":25026,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25025\/revisions\/25026"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}